NEUROCRINE BIOSCIENCES INC

For the period ended Dec 31, 2025. Filed Feb 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 11, 2026

NBIX$168.86+2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
(in millions, except per share data)	2025	2024
Assets
Current assets:
Cash and cash equivalents	$713.0	$233.0
Available-for-sale debt securities	767.4	843.1
Accounts receivable	686.8	479.1
Inventory	69.0	57.4
Prepaid expenses	170.7	48.5
Other current assets	115.8	63.6
Total current assets	2,522.7	1,724.7
Deferred tax assets	320.3	485.7
Available-for-sale debt securities	1,063.0	739.5
Right-of-use assets	455.4	509.4
Equity investments	120.8	124.8
Property and equipment, net	89.8	82.6
Other noncurrent assets	59.5	52.0
Total assets	$4,631.5	$3,718.7
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$674.3	$461.6
Other current liabilities	69.1	46.1
Total current liabilities	743.4	507.7
Noncurrent operating lease liabilities	415.3	455.1
Other noncurrent liabilities	219.7	166.2
Total liabilities	1,378.4	1,129.0
Stockholders’ equity:
Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding	—	—
Common stock, $0.001 par value; 220.0 shares authorized; 100.1 and 99.4 shares issued and outstanding, respectively	0.1	0.1
Additional paid-in capital	2,792.2	2,554.6
Accumulated other comprehensive income	13.1	5.8
Retained earnings	447.7	29.2
Total stockholders’ equity	3,253.1	2,589.7
Total liabilities and stockholders’ equity	$4,631.5	$3,718.7

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.